{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:38:18Z","timestamp":1776137898745,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ccm.2020.05.007","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T18:12:05Z","timestamp":1597255925000},"page":"485-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic Medications in Chronic Obstructive Pulmonary Disease"],"prefix":"10.1016","volume":"41","author":[{"given":"Nicolas","family":"Roche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2020.05.007_bib1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. Available at: https:\/\/goldcopd.org."},{"key":"10.1016\/j.ccm.2020.05.007_bib2","first-page":"995","article-title":"Novel aspects of pathogenesis and regeneration mechanisms in COPD","volume":"10","author":"Bagdonas","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ccm.2020.05.007_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/17476348.2017.1360769","article-title":"Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox","volume":"11","author":"Eapen","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0032-2018","article-title":"The consequence of matrix dysfunction on lung immunity and the microbiome in COPD","volume":"27","author":"Hussell","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2020.05.007_bib5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1701632","article-title":"Airway mucin concentration as a marker of chronic bronchitis","volume":"377","author":"Kesimer","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/COPD.S42414","article-title":"COPD: balancing oxidants and antioxidants","volume":"10","author":"Fischer","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ccm.2020.05.007_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1146\/annurev-physiol-022516-034314","article-title":"Senescence in COPD and its comorbidities","volume":"79","author":"Barnes","year":"2017","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ccm.2020.05.007_bib8","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.chest.2017.10.033","article-title":"Autoimmunity and COPD: clinical implications","volume":"153","author":"Caramori","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2020.05.007_bib9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00128008","article-title":"Systemic manifestations and comorbidities of COPD","volume":"33","author":"Barnes","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.007_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2018","article-title":"Cardiovascular disease and COPD: dangerous liaisons?","volume":"27","author":"Rabe","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2020.05.007_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejphar.2018.10.001","article-title":"Psychological co-morbidities in COPD: targeting systemic inflammation, a benefit for both?","volume":"842","author":"Pelgrim","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ccm.2020.05.007_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.resinv.2016.07.001","article-title":"Prevalence and burden of comorbidities in chronic obstructive pulmonary disease","volume":"54","author":"Corlateanu","year":"2016","journal-title":"Respir Investig"},{"key":"10.1016\/j.ccm.2020.05.007_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2013-204763","article-title":"Determinants and outcomes of physical activity in patients with COPD: a systematic review","author":"Gimeno-Santos","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2020.05.007_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-019-1017-y","article-title":"The pathology of small airways disease in COPD: historical aspects and future directions","volume":"20","author":"Higham","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.ccm.2020.05.007_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s002280050561","article-title":"Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease","volume":"54","author":"Cazzola","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ccm.2020.05.007_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0002-9343(83)90459-X","article-title":"Bronchodilator response to oral aminophylline and terbutaline versus aerosol albuterol in patients with chronic obstructive pulmonary disease","volume":"75","author":"Shim","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2016_71","article-title":"Xanthines and phosphodiesterase inhibitors","volume":"237","author":"Spina","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ccm.2020.05.007_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4187\/respcare.06068","article-title":"Clinical pharmacology of oral maintenance therapies for obstructive lung diseases","volume":"63","author":"Pleasants","year":"2018","journal-title":"Respir Care"},{"key":"10.1016\/j.ccm.2020.05.007_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0010-2018","article-title":"Efficacy and safety profile of xanthines in COPD: a network meta-analysis","volume":"27","author":"Cazzola","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2020.05.007_bib20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1084\/jem.20040416","article-title":"Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages","volume":"200","author":"Cosio","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib22","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"373","author":"Barnes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2020.05.007_bib23","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa041892","article-title":"Decreased histone deacetylase activity in chronic obstructive pulmonary disease","volume":"352","author":"Ito","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/jama.2018.14432","article-title":"Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial","volume":"320","author":"Devereux","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2020.05.007_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2016.04.011","article-title":"Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial","author":"Cos\u00edo","year":"2016","journal-title":"Chest"},{"issue":"9278","key":"10.1016\/j.ccm.2020.05.007_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2020.05.007_bib27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(05)17708-3","article-title":"Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease","volume":"365","author":"Lipworth","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2020.05.007_bib28","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2174\/1381612823666170214105651","article-title":"Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences","volume":"23","author":"Contreras","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.ccm.2020.05.007_bib29","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","author":"Chong","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2020.05.007_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). a randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/13543784.2019.1661990","article-title":"Ensifentrine (RPL554): an investigational PDE3\/4 inhibitor for the treatment of COPD","volume":"28","author":"Cazzola","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ccm.2020.05.007_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib34","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4187\/respcare.05943","article-title":"Prophylactic antibiotic use in COPD and the potential anti-inflammatory activities of antibiotics","volume":"63","author":"Huckle","year":"2018","journal-title":"Respir Care"},{"key":"10.1016\/j.ccm.2020.05.007_bib36","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.2147\/COPD.S181246","article-title":"Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis","volume":"13","author":"Cui","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ccm.2020.05.007_bib37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1378\/chest.120.3.730","article-title":"Erythromycin and common cold in COPD","volume":"120","author":"Suzuki","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2020.05.007_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","article-title":"Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy","volume":"189","author":"Han","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","article-title":"Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Sethi","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.ccm.2020.05.007_bib40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09059180.00003610","article-title":"Mucoactive therapy in COPD","volume":"19","author":"Decramer","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2020.05.007_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/15412555.2017.1347918","article-title":"Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis","volume":"14","author":"Cazzola","year":"2017","journal-title":"COPD"},{"key":"10.1016\/j.ccm.2020.05.007_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.007_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1183\/09031936.01.17303370","article-title":"Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids","volume":"17","author":"Schols","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.007_bib44","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1164\/ajrccm.157.6.9705017","article-title":"Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease","volume":"157","author":"Schols","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.007_bib45","article-title":"Oral corticosteroids for stable chronic obstructive pulmonary disease","author":"Walters","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2020.05.007_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00408-015-9743-5","article-title":"The effectiveness of anti-leukotriene agents in patients with COPD: a systemic review and meta-analysis","volume":"193","author":"Lee","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.ccm.2020.05.007_bib47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction","volume":"339","author":"Gottlieb","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib48","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD","volume":"381","author":"Dransfield","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib49","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","article-title":"Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1513\/AnnalsATS.201604-317OC","article-title":"Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. The multi-ethnic study of atherosclerosis lung study","volume":"14","author":"Parikh","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ccm.2020.05.007_bib51","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.jaci.2018.04.020","article-title":"Biologics and chronic obstructive pulmonary disease","volume":"141","author":"Pavord","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.ccm.2020.05.007_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/15412555.2018.1437897","article-title":"Biologic drugs: a new target therapy in COPD?","volume":"15","author":"Yousuf","year":"2018","journal-title":"COPD"},{"key":"10.1016\/j.ccm.2020.05.007_bib53","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","article-title":"Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management","volume":"385","author":"Woodruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2020.05.007_bib54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.007_bib55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.rmed.2012.11.008","article-title":"Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease","volume":"107","author":"Rennard","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000117386","article-title":"Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study","volume":"76","author":"Dentener","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.ccm.2020.05.007_bib57","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2020.05.007_bib58","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00610-2017","article-title":"European Respiratory Society statement: diagnosis and treatment of pulmonary disease in \u03b11-antitrypsin deficiency","volume":"50","author":"Miravitlles","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.007_bib59","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2147\/COPD.S112484","article-title":"Prescription of opioids for breathlessness in end-stage COPD: a national population-based study","volume":"11","author":"Ahmadi","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ccm.2020.05.007_bib60","article-title":"Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness","volume":"2016","author":"Barnes","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523120300332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523120300332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:58:52Z","timestamp":1759453132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523120300332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0272523120300332"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2020.05.007","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Medications in Chronic Obstructive Pulmonary Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2020.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}